Fig. 2: Kaplan–Meier curve for the population of patients with bTMB ≥16. | Nature Medicine

Fig. 2: Kaplan–Meier curve for the population of patients with bTMB ≥16.

From: Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Fig. 2: Kaplan–Meier curve for the population of patients with bTMB ≥16.

a, Primary endpoint: investigator-assessed PFS. Statistical analysis used a stratified log-rank test at the two-sided 0.05 level and was not adjusted for multiple comparisons. b, Key secondary endpoint: OS. Statistical analysis used a stratified log-rank test at the two-sided 0.05 level and was not adjusted for multiple comparisons. Atezo, atezolizumab; Chemo, chemotherapy. P values for milestone PFS are descriptive.

Back to article page